We determined that treatment with cetuximab significantly enhanced the cytotoxicity of RSL3 in KRAS-mutated CRC cells and promoted RSL3-induced ferroptosis by suppressing Nrf2/HO-1 expression. The gene discussed is NFE2L2; the disease is colorectal carcinoma.